Viewing nowCombinationOlomax Tablet 20/5/10 mg (Olmesartan Medoxomil, Amlodipine, Rosuvastatin)
Olmesartan Medoxomil 20mg · Amlodipine Besylate 6.95mg +1 more
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.

MFDS item code 201901264 · Approved 2019.02.27 · Insurance code 641606760
Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and reduction of cardiovascular disease risk
This drug is used for patients who have difficulty achieving sufficient blood pressure control for hypertension treatment with olmesartan medoxomil and amlodipine combination, while simultaneously needing to administer rosuvastatin. The olmesartan medoxomil and amlodipine combination is effective for the treatment of essential hypertension. Rosuvastatin is primarily used as an adjunctive treatment in the dietary therapy of patients with hypercholesterolemia and hyperlipidemia. Additionally, it helps slow the progression of atherosclerosis and reduce the risk of cardiovascular disease in patients with hypercholesterolemia, particularly contributing to the reduction of the risk of myocardial infarction, stroke, and angioplasty. Therefore, this drug improves cardiovascular health by managing blood pressure and cholesterol levels together.
This medicine should be taken once daily as 1 tablet with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the olmesartan medoxomil/amlodipine combination and rosuvastatin. For patients taking olmesartan medoxomil/amlodipine in combination with rosuvastatin, they may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience. ◆ Olmesartan medoxomil/amlodipine combination Before administering this medicine, it is recommended that the dose be adjusted using the individual components (olmesartan medoxomil or amlodipine). However, if blood pressure is not adequately controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 40/10 milligrams. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. (olmesartan medoxomil/amlodipine) - 20/5 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams or amlodipine 5 milligrams as monotherapy. - 40/5 milligrams: For patients whose blood pressure is not adequately controlled with 20/5 milligrams. - 40/10 milligrams: For patients whose blood pressure is not adequately controlled with 40/5 milligrams. ∘ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘ Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘ Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should be closely monitored for blood pressure and renal function. This medicine should not be administered to patients with severe hepatic impairment. (See the section “Do not administer to the following patients” under Precautions for Use.) ∘ Elderly patients: In general, treatment should be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. In elderly patients, blood pressure should be monitored closely and more frequently. ◆ Rosuvastatin ∘ Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose for adults is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 milligrams once daily. ∘ Elderly patients: No dose adjustment is necessary. ∘ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20mg to patients with moderate renal impairment. ∘ Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. ∘ Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. ∘ Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of rosuvastatin 40 milligrams is contraindicated in some of these patients.
This drug may cause serious harm to the fetus and newborn when administered to women in the second and third trimesters of pregnancy; therefore, if pregnancy is confirmed, it should be discontinued immediately. Patients with an allergy to the active ingredient or components of this drug, women who are pregnant or breastfeeding, and patients with severely impaired liver or kidney function should not use it. Especially, patients on dialysis or with severe kidney failure, patients with certain cardiac conditions, and patients with muscle disorders may also be at risk if they take this drug, hence it should be avoided. Patients with genetic conditions such as lactose intolerance should also refrain from taking this drug. Patients who are dehydrated or have low salt levels must be monitored closely as they may experience hypotension upon initial dosing. Patients with specific heart valve diseases need special caution as vascular expansion may lead to acute hypotension during the administration of this drug. Patients with heart failure or severe obstructive coronary artery disease should also be administered carefully as their symptoms may worsen. Patients with kidney function issues should regularly monitor serum potassium and creatinine levels, and consult healthcare professionals immediately if abnormalities arise. Patients with reduced liver function must be careful when taking this drug, and should notify their healthcare provider immediately if liver function impairment symptoms appear. One of the ingredients in this drug may cause myalgia, myopathy, and rarely severe muscle damage; therefore, if muscle pain or weakness occurs, the medication should be stopped immediately and a doctor consulted. This drug lowers blood pressure, so when taken with other antihypertensive medications, blood pressure may drop too low, requiring caution. Taking this drug alongside specific diuretics or potassium-sparing medications may lead to dangerously elevated potassium levels, hence those taking such medications should inform their healthcare provider. Taking this drug with grapefruit juice may increase its serum concentration, heightening the risk of side effects; therefore, it is best to avoid grapefruit juice. While this drug is known not to significantly affect driving or operating machinery, caution is advised if symptoms such as dizziness occur. Monitoring kidney, liver, and muscle conditions through regular health check-ups is important while taking this medication.
Palpitations, upper abdominal pain, vomiting, fatigue, peripheral edema, bacterial pneumonia, subarachnoid hemorrhage, increased ALT, increased AST, hypoglycemia, dizziness, headache, hematuria, allergic rhinitis, cough, wet cough, rash, arterial embolism, drug hypersensitivity reaction, hyperkalemia, decreased libido, orthostatic hypotension, drowsiness, sensory disturbances, sensory deficits, syncope, vertigo, chest palpitations, rapid pulse, hypotension, orthostatic hypotension, dyspnea, indigestion, diarrhea, constipation, dry mouth, urticaria, muscle tension, limb pain, low back pain, erectile dysfunction, edema, dependent edema, fatigue, facial edema, decreased serum potassium, increased serum creatinine, increased serum uric acid, elevated gamma-glutamyl transferase, decreased hemoglobin, decreased hematocrit, multiple organ dysfunction syndrome, viral pneumonia, benign neoplasm, malignant neoplasm, neoplasm of unknown origin, adrenal adenoma, oropharyngeal discomfort, low back pain, bronchitis, increased creatine phosphokinase, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, sinusitis, hair loss, itching, urticaria, autoimmune hepatitis, fatigue, angioedema, vomiting, chronic malabsorption syndrome, intestinal vascular edema, rhabdomyolysis, acute renal failure, elevated serum creatinine, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, thrombocytopenia, hematuria, edema, depression, sleep disorders, insomnia, nightmares, interstitial lung disease, sexual dysfunction, gynecomastia, fatal liver failure, non-fatal liver failure, memory impairment, forgetfulness, amnesia, memory disorder, confusion, myalgia, myopathy, myositis, muscle weakness, muscle cramps, gout, chest discomfort, loss of appetite, abdominal distension, abnormal liver function tests, syncope, generalized pain, arthralgia
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly sealed container to prevent air or moisture from entering, at a temperature between 1 to 30 degrees Celsius. Doing so helps maintain the effectiveness of the medication over time.
White to pinkish round film-coated tablets
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.95mg +1 more
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.95mg +1 more
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.95mg +1 more
Tablet · Prescription medication · Combination
Daewong Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.95mg +1 more
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.